ArticleLaryngoscope investigative otolaryngology2026
Post-Vaccination Chemosensory Dysfunction: Changes Following SARS-CoV-2 Vaccination in a Global Study.
Article in Laryngoscope investigative otolaryngology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess post-vaccination changes in chemosensory function among individuals with and without COVID-19-related chemosensory impairment. Methods: In this global, multilingual online survey, participants reported vaccination status, vaccine side effects, and changes in smell and taste before and after each vaccine dose. Responses were collected between May 2022 and August 2023 through convenience sampling. Of 2955 responses, 1352 were included after applying exclusion criteria. Results: Pfizer-BioNTech accounted for 46.2% of vaccine doses, followed by Sputnik V (16.3%), Moderna (15.4%), AstraZeneca (8.9%), and Sinopharm (7.4%). More than 90% of participants reported no change in general smell or taste following vaccination, regardless of pre-existing chemosensory impairment. Among participants with qualitative chemosensory distortions, improvement was reported by 11%-18% for parosmia, 20%-29% for phantosmia, and 12%-21% for distorted taste, depending on vaccine dose, whereas worsening was reported by 3% or fewer. Side effects varied by vaccine type and were more frequent among individuals reporting worsened chemosensory symptoms. Conclusion: Most participants reported stable smell and taste perception following vaccination. A subset of individuals with qualitative chemosensory distortions reported improvement, while worsening was uncommon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.